Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
    Zhu, You-cai
    Liao, Xing-hui
    Wang, Wen-xian
    Xu, Chun-wei
    Zhuang, Wu
    Zhong, Li-hua
    Du, Kai-qi
    Chen, Yan-ping
    Chen, Gang
    Fang, Mei-yu
    ONCOTARGETS AND THERAPY, 2017, 10 : 3187 - 3192
  • [12] Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review
    Xu, Chun-wei
    Wang, Wen-xian
    Huang, Rong-fang
    He, Cheng
    Liao, Xing-hui
    Zhu, You-cai
    Du, Kai-qi
    Zhuang, Wu
    Chen, Yan-ping
    Chen, Gang
    Fang, Mei-yu
    THORACIC CANCER, 2017, 8 (06) : 714 - 719
  • [13] Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib A case report
    Yang, Tao
    Xu, Rui
    Yan, Bing
    Li, Fang
    Liu, Hui
    MEDICINE, 2018, 97 (52)
  • [14] ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
    Xu, Shuguang
    Wang, Wenxian
    Xu, Chunwei
    Li, Xingliang
    Ye, Junhui
    Zhu, Youcai
    Ge, Ting
    BMC CANCER, 2019, 19 (01)
  • [15] ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
    Shuguang Xu
    Wenxian Wang
    Chunwei Xu
    Xingliang Li
    Junhui Ye
    Youcai Zhu
    Ting Ge
    BMC Cancer, 19
  • [16] Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
    Joshua, Julie Mariam
    Salima, K. D.
    Pavithran, K.
    Vijayan, Meenu
    CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2018, 11 : 1 - 3
  • [17] Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
    Ryu, Woo Kyung
    Cha, Hyungkeun
    Park, Mi Hwa
    Kim, Jung Soo
    Choi, Jeong-Seok
    Kim, Lucia
    Lee, Kyung-Hee
    Nam, Hae-Seong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [18] Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion
    Wei, Shuli
    Hu, Mangsha
    Yang, Yan
    Huang, Xiaojie
    Li, Baizhou
    Ding, Liren
    Wang, Pingli
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [19] EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results
    Michels, Sebastian
    Gardizi, Masyar
    Schmalz, Petra
    Thurat, Meike
    Pereira, Eva
    Sebastian, Martin
    Carcereny, Enric
    Corral, Jesus
    Paz-Ares, Luis
    Felip, Enriqueta
    Grohe, Christian
    Rodriguez Abreu, Delvys
    Insa Molla, Amelia
    Bischoff, Helge
    Reck, Martin
    Karachaliou, Niki
    Scheel, Andreas
    Brandes, Vanessa
    Rieke, Fischer
    Nogova, Lucia
    Scheffler, Matthias
    Franklin, Jeremy
    Hellmich, Martin
    Massuti, Bartomeu
    Buettner, Reinhard
    Rosell, Rafael
    Wolf, Juergen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S379 - S380
  • [20] Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review
    Zhu, You-cai
    Lin, Xue-ping
    Li, Xiao-feng
    Wu, Li-xin
    Chen, Hua-fei
    Wang, Wen-xian
    Xu, Chun-wei
    Shen, Jian-fa
    Wei, Jian-guo
    Du, Kai-qi
    THORACIC CANCER, 2018, 9 (01) : 159 - 163
12345